Biotest Pharmaceuticals Corporation Announces Acquisition of Biotest US Corporation by Grifols Shared Services North America, Inc.

BOCA RATON, FL, August 1, 2018 – Biotest Pharmaceuticals Corporation (BPC), a wholly owned subsidiary of Biotest US Corporation (“Biotest USA”), and a leader in the collection of Source Plasma, is pleased to announce that Grifols Shared Services North America, Inc., a wholly owned subsidiary of Grifols, S.A. has completed its acquisition of Biotest USA for $286 Million in cash.  This acquisition comprises 22 Biotest plasma collection centers, 2 centers under construction and 2 centers under purchase contract as well as corporate offices located in Boca Raton, Florida and more than 900 US employees.

Following this acquisition, BPC will continue to operate as Biotest Pharmaceuticals Corporation until all FDA regulatory approvals have been obtained.

“We are excited to be part of the Grifols prestigious global organization and remain steadfast on our mission to secure a quality supply of the raw materials needed to help the thousands of patients that rely on plasma based therapies” said Ileana Carlisle, BPC’s Chief Executive Officer.

The plasma collected at Biomat USA Plasma Centers is used to manufacture critical care therapies that treat life threatening disorders in a variety of therapeutic areas.

About Biotest Pharmaceuticals Corporation

Biotest Pharmaceuticals Corporation (BPC), headquartered in Boca Raton, Florida, owns and operates plasmapheresis centers in 12 states with over 900 employees across the U.S.   In 2017, BPC collected approximately 850,000 liters of plasma from its plasma centers. We are committed to continuing to serve the thousands of patients worldwide who rely on plasma-based therapies. To learn more about Biotest Pharmaceuticals, our Plasma Centers, and the difference we make in the lives of patients and the healthcare community, please visit us at and